thalidomide has been researched along with Intestinal Diseases in 14 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Intestinal Diseases: Pathological processes in any segment of the INTESTINE from DUODENUM to RECTUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Thalidomide has been evaluated for the treatment of recurrent bleeding due to small-intestinal angiodysplasia (SIA), but confirmatory trials are lacking." | 9.69 | Thalidomide for Recurrent Bleeding Due to Small-Intestinal Angiodysplasia. ( Chen, H; Dai, Z; Du, Y; Gao, Y; Ge, Z; Gong, S; Li, X; Li, Z; Liu, S; Lu, H; Lu, L; Shen, X; Shen, Y; Tang, M; Wu, S; Xiong, H; Xu, L; Xue, H; Yang, A; Yang, S; Zhang, Q; Zhao, R; Zhong, J; Zhong, L, 2023) |
| "We studied the effect of thalidomide on the macroscopic appearance of angiodysplasias in three patients with bleeding due to multiple angiodysplasias of the small intestine." | 7.73 | Macroscopic appearance of intestinal angiodysplasias under antiangiogenic treatment with thalidomide. ( Bauditz, J; Lochs, H; Voderholzer, W, 2006) |
| " Thalidomide has been evaluated for the treatment of recurrent bleeding due to small-intestinal angiodysplasia (SIA), but confirmatory trials are lacking." | 5.69 | Thalidomide for Recurrent Bleeding Due to Small-Intestinal Angiodysplasia. ( Chen, H; Dai, Z; Du, Y; Gao, Y; Ge, Z; Gong, S; Li, X; Li, Z; Liu, S; Lu, H; Lu, L; Shen, X; Shen, Y; Tang, M; Wu, S; Xiong, H; Xu, L; Xue, H; Yang, A; Yang, S; Zhang, Q; Zhao, R; Zhong, J; Zhong, L, 2023) |
| "We studied the effect of thalidomide on the macroscopic appearance of angiodysplasias in three patients with bleeding due to multiple angiodysplasias of the small intestine." | 3.73 | Macroscopic appearance of intestinal angiodysplasias under antiangiogenic treatment with thalidomide. ( Bauditz, J; Lochs, H; Voderholzer, W, 2006) |
| "Thalidomide is suggested to be a concomitant therapy with IFX for intestinal BS patients." | 1.91 | Predictors of infliximab refractory intestinal Behçet's syndrome: A retrospective cohort study from the Shanghai Behçet's syndrome database. ( Bao, HF; Cai, JF; Guan, JL; Hou, CC; Luo, D; Shen, Y; Ye, B; Zou, J, 2023) |
| " The clinical response and adverse events of the thalidomide treatment were recorded." | 1.56 | CYP2C19 polymorphism has no correlation with the efficacy and safety of thalidomide in the treatment of immune-related bowel disease. ( Chen, BL; Chen, MH; Feng, R; He, Y; Mao, R; Qiu, Y; Xu, PP; Zeng, ZR; Zhang, SH, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (21.43) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 5 (35.71) | 2.80 |
| Authors | Studies |
|---|---|
| Bao, HF | 1 |
| Hou, CC | 1 |
| Ye, B | 1 |
| Zou, J | 1 |
| Luo, D | 1 |
| Cai, JF | 1 |
| Shen, Y | 2 |
| Guan, JL | 1 |
| Chen, H | 2 |
| Wu, S | 1 |
| Tang, M | 1 |
| Zhao, R | 1 |
| Zhang, Q | 1 |
| Dai, Z | 1 |
| Gao, Y | 1 |
| Yang, S | 1 |
| Li, Z | 1 |
| Du, Y | 1 |
| Yang, A | 1 |
| Zhong, L | 1 |
| Lu, L | 1 |
| Xu, L | 1 |
| Shen, X | 1 |
| Liu, S | 1 |
| Zhong, J | 1 |
| Li, X | 1 |
| Lu, H | 1 |
| Xiong, H | 1 |
| Gong, S | 1 |
| Xue, H | 1 |
| Ge, Z | 1 |
| Feng, R | 1 |
| Xu, PP | 1 |
| Chen, BL | 1 |
| Mao, R | 1 |
| Zhang, SH | 1 |
| Qiu, Y | 1 |
| Zeng, ZR | 1 |
| Chen, MH | 1 |
| He, Y | 2 |
| Wei, Q | 1 |
| Zhang, X | 1 |
| Peng, Y | 1 |
| Chen, K | 1 |
| Xu, S | 1 |
| Huang, X | 1 |
| Zhang, L | 1 |
| Xie, Q | 1 |
| Li, Y | 1 |
| Chai, J | 1 |
| Fukui, S | 1 |
| Kawaai, S | 1 |
| Tamaki, H | 1 |
| Fukuda, K | 1 |
| Okada, M | 1 |
| Sakkas, LI | 1 |
| Mavropoulos, A | 1 |
| Bogdanos, DP | 1 |
| Fernández Salazar, LI | 1 |
| Velayos Jiménez, B | 1 |
| Fernández Galante, I | 1 |
| Aller de la Fuente, R | 1 |
| González Hernández, JM | 1 |
| Gerson, LB | 1 |
| Jackson, C | 1 |
| IMDAHL, H | 1 |
| HERMANNS, A | 1 |
| KOCH, W | 1 |
| SURUGA, K | 1 |
| MICHAELIS, R | 1 |
| TARNOW, G | 1 |
| Bauditz, J | 1 |
| Lochs, H | 1 |
| Voderholzer, W | 1 |
| Lopez, J | 1 |
| Ulibarrena, C | 1 |
| Garcia-Laraña, J | 1 |
| Odriozola, J | 1 |
| Pérez de Oteyza, J | 1 |
| Sastre, JL | 1 |
| Navarro, JL | 1 |
| Travis, SP | 1 |
| Czajkowski, M | 1 |
| McGovern, DP | 1 |
| Watson, RG | 1 |
| Bell, AL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Phase II Trial Evaluating the Efficiency of Pasireotide for the Treatment of Gastrointestinal Angiodysplasia in Endoscopic Treatment Failure[NCT02622906] | Phase 2 | 24 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for thalidomide and Intestinal Diseases
| Article | Year |
|---|---|
Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives.
Topics: Aminopyridines; Autoimmune Diseases; Benzamides; Boron Compounds; Cyclopropanes; Eye Diseases; Human | 2017 |
1 trial available for thalidomide and Intestinal Diseases
| Article | Year |
|---|---|
Thalidomide for Recurrent Bleeding Due to Small-Intestinal Angiodysplasia.
Topics: Administration, Oral; Angiodysplasia; China; Double-Blind Method; Gastrointestinal Hemorrhage; Hemat | 2023 |
12 other studies available for thalidomide and Intestinal Diseases
| Article | Year |
|---|---|
Predictors of infliximab refractory intestinal Behçet's syndrome: A retrospective cohort study from the Shanghai Behçet's syndrome database.
Topics: Behcet Syndrome; China; Humans; Infliximab; Intestinal Diseases; Retrospective Studies; Thalidomide; | 2023 |
CYP2C19 polymorphism has no correlation with the efficacy and safety of thalidomide in the treatment of immune-related bowel disease.
Topics: Adult; Behcet Syndrome; Colitis, Ulcerative; Crohn Disease; Cytochrome P-450 CYP2C19; Female; Genoty | 2020 |
Successful treatment by thalidomide therapy of intestinal Behçet's disease associated with trisomy 8 myelodysplastic syndrome.
Topics: Behcet Syndrome; Chromosomes, Human, Pair 8; Female; Humans; Immunosuppressive Agents; Intestinal Di | 2021 |
A novel combination treatment with apremilast and tumor necrosis factor inhibitor for a patient with refractory intestinal Behcet's disease.
Topics: Behcet Syndrome; Humans; Intestinal Diseases; Thalidomide; Tumor Necrosis Factor Inhibitors | 2022 |
[Efficacy of thalidomide in digestive bleeding caused by angiodysplasias].
Topics: Aged; Angiodysplasia; Angiogenesis Inhibitors; Cardiovascular Diseases; Cerebellar Neoplasms; Cerebe | 2009 |
Time to consider medical therapy for small-bowel angioectasias.
Topics: Gastrointestinal Agents; Humans; Intestinal Diseases; Intestine, Small; Octreotide; Thalidomide; Vas | 2012 |
[THALIDOMIDE AND RECTO-ANAL ATRESIA].
Topics: Abnormalities, Drug-Induced; Anal Canal; Anus, Imperforate; Biometry; Germany; Germany, West; Infant | 1963 |
[THALIDOMIDE ABNORMALITIES].
Topics: Abnormalities, Drug-Induced; Child; Child Care; Child Welfare; Ectromelia; Humans; Infant, Newborn; | 1964 |
[NEUROLOGICAL DISEASES AS SEQUELS TO CONTERGAN USE IN DISORDERS OF INTESTINAL RESORPTION].
Topics: Central Nervous System Diseases; Gastric Acidity Determination; Gastritis; Intestinal Diseases; Neur | 1963 |
Macroscopic appearance of intestinal angiodysplasias under antiangiogenic treatment with thalidomide.
Topics: Aged; Aged, 80 and over; Angiodysplasia; Angiogenesis Inhibitors; Capsule Endoscopy; Disease Progres | 2006 |
Thalidomide as therapy for intestinal chronic GVHD.
Topics: Adult; Bone Marrow Transplantation; Graft vs Host Disease; Humans; Intestinal Diseases; Male; Precur | 1993 |
Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody.
Topics: Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Behcet Syndrome; Drug Therapy, Combination; | 2001 |